C3F
A neo-epitope fragment of type III collagen generated by fibroblast activation protein (FAP) activity, enabling non-invasive assessment of fibroblast-driven extracellular matrix remodeling in fibrotic and oncologic conditions.
Key features and values
- Quantifies specific fragments of type III collagen produced by FAP-mediated cleavage.
- Reflects fibroblast activation and extracellular matrix remodeling associated with fibrotic and cancerous tissues.
- Provides a non-invasive measure of FAP enzymatic activity in various pathological conditions.
- Supports monitoring of disease progression and response to therapies targeting fibroblast activity.
- Applicable in research on diseases characterized by excessive fibroblast activation, such as certain cancers and fibrotic disorders.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix remodeling.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The C3F biomarker assay measures specific neo-epitope fragments of type III collagen generated through fibroblast activation protein (FAP) activity, serving as an indicator of fibroblast-driven extracellular matrix remodeling. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as cancer and fibrosis. By quantifying collagen degradation products associated with FAP activity, the C3F assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of fibroblast activation and extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
